it is an ion exchange resin is an orally administered bile acid sequestrant that is being developed by mitsubishi tanabe pharma corporation for the treatment of hypercholesterolaemia and hyperphosphataemia it has been launched in japan for hypercholesterolaemia for the treatment of hyperphosphataemia it is launched in austria germany the czech republic portugal and the united kingdom is registered in the eu phase iii development in paediatric patients with hyperphosphataemia associated with chronic kidney disease was underway in the uk and germany however the company discontinued the development in addition the phase ii development in type 2 diabetes mellitus and phase i development in hyperphosphataemia in japan was also discontinued by the company phase iii development for hyperphosphataemia was previously underway in the us however mitsubishi tanabe pharma discontinued development in this market colestilan was also investigated in phase iii trials in europe and asia for hypercholesterolaemia however as of march 2015 no recent reports of development have been identified for the drug in this indication colestilan is used for the treatment of hyperphosphataemia too high phosphate concentrations in the blood serum in patients undergoing dialysis including peritoneal dialysis colestilan is contraindicated in patients with bowel obstruction the substance can inhibit